A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| CJ-15161 | CJ-15161 is a κ-opioid receptor agonist. Synonyms: CJ 15161; CJ15161; 4-(((S)-2-((S)-3-Hydroxypyrrolidin-1-yl)-1-phenylethyl)(methyl)amino)-N-propylbenzamide. CAS No. 204970-97-8. Molecular formula: C23H31N3O2. Mole weight: 381.52. |  |
| CJ-15183 | CJ-15183 is originally isolated from Aspergillus aculeatus CL38916. It has strong inhibitory activity against rat liver, human liver and Candida albicans SSase, and has antifungal activity against filamentous fungi and yeast-like fungi. Molecular formula: C28H38O13. Mole weight: 582.59. | |
| CJ-15208 | CJ-15208 is produced by the strain of Ctenomyces serratus. It selectively inhibits κ-opioid receptor binding with an IC50 of 47 nmol/L. Synonyms: (3S,6S,9S,14aR)-6-((1H-indol-3-yl)methyl)-3,9-dibenzyldecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone; c[L-Phe-D-pro-L-Phe-L-trp]. CAS No. 210236-47-8. Molecular formula: C34H35N5O4. Mole weight: 577.67. | |
| CJ 15544 | CJ 15544 is a potent κ-opioid receptor antagonist from a fungus, Hericium ramosum CL 24240. Synonyms: Antibiotic CJ 15544. Molecular formula: C25H34O6. Mole weight: 430.53. | |
| CJ-15696 | CJ-15696 is a furopyridine antibiotic produced by the strain of Cladobotryum varium CL12284. It has moderate activity against gram-positive bacteria, including drug-resistant bacteria. Molecular formula: C19H19NO3. Mole weight: 309.36. | |
| CJ-15801 | It is originally isolated from Seimatosporium sp. CL28611. CJ-15801 has only anti-MRSA activity with MIC of 6.25-50 μg/mL. Synonyms: CJ-15,801; BDBM50285609; 3-[[(R)-2,4-Dihydroxy-3,3-dimethylbutanoyl]amino]acrylic acid. Molecular formula: C9H15NO5. Mole weight: 217.22. | |
| CJ-16169 | CJ-16169 is a furopyridine antibiotic produced by the strain of Cladobotryum varium CL12284. It has weak activity against gram-positive bacteria. Molecular formula: C19H21NO3. Mole weight: 311.37. | |
| CJ-16170 | CJ-16170 is a furopyridine antibiotic produced by the strain of Cladobotryum varium CL12284. It has weak activity against gram-positive bacteria. Molecular formula: C19H21NO3. Mole weight: 311.37. | |
| CJ-16173 | CJ-16173 is a furopyridine antibiotic produced by the strain of Cladobotryum varium CL12284. It has weak activity against gram-positive bacteria. Molecular formula: C19H19NO4. Mole weight: 325.36. | |
| CJ-16367 | It is originally isolated from CL39457. CJ-16367 is mainly resistant to Gram-positive bacteria, including multi-drug resistant strains, but its activity is weak. Molecular formula: C23H31NO5. Mole weight: 401.49. | |
| CJ-17572 | It is produced by the strain of Pezicula sp. CJ-11877. CJ-17572 has anti-MRSA and Enterococcus faecalis activity with MIC of 10-20 μg/mL. Synonyms: 3-[hydroxy(1,2,6-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl)methylidene]-5-(1-hydroxyethyl)-1-methylpyrrolidine-2,4-dione. Molecular formula: C21H31NO4. Mole weight: 361.47. | |
| CJ-17665 | CJ-17665 is produced by the strain of Aspergillus ochraceus. It inhibits growth of multi-drug resistant MRSA, Streptococcus pyogenes and Enterococcus faecalis with MIC of 12.5, 12.5 and 25 μg/mL, respectively. Molecular formula: C26H33N3O4. Mole weight: 451.56. | |
| CJ-19784 | CJ-19784 is an antibiotic which is mainly resistant to Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. It is produced by the strain of Acanthostigmella sp. CL-12082. Synonyms: 4H-1-Benzopyran-4-one,2-(3-bromo-2-hydroxyphenyl)-5-hydroxy-3,7,8-trimethoxy. CAS No. 399509-71-8. Molecular formula: C18H15BrO7. Mole weight: 423.21. | |
| CJ-21058 | CJ-21058 is a SecA inhibitor originally isolated from CL47745. It shows antiprotozoal effects (IC50 = 7 μM, T. brucei) and inhibits post-translational protein transport into the endoplasmic reticulum. It shows antibacterial and antifungal effects in vivo. Synonyms: CHEMBL565009; (5R,Z)-3-(Hydroxy((1R,2S,6S,8aS)-1,3,6-trimethyl-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-octahydro-naphthalen-1-yl)methylene)-5-(hydroxymethyl)-1-methylpyrrolidine-2,4-dione. Grade: >98% by HPLC. CAS No. 405072-57-3. Molecular formula: C23H33NO4. Mole weight: 387.51. | |
| CJ-21058 ((5R, Z)-3-(Hydroxy((1R, 2S, 6S, 8aS)-1, 3, 6-trimethyl-2-((E)-prop-1-en-1-yl)-1, 2, 4a, 5, 6, 7, 8, 8a-octahydro-naphthalen-1-yl)methylene)-5-(hydroxymethyl)-1-methylpyrrolidine-2, 4-dione) | Antibiotic. SecA inhibitor. Antibacterial and antifungal. Cytotoxic. Methyl analog of equisetin. Group: Biochemicals. Grades: Highly Purified. CAS No. 405072-57-3. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. |  Worldwide |
| CJ-21164 | It is produced by the strain of Chloridium sp. CL48903. The IC50 of CJ-21164 inhibiting G6Pase in rat liver microsomes was 1.6 μmol/L. Synonyms: CHEMBL3218304. Molecular formula: C38H37ClO14. Mole weight: 753.14. | |
| CJ-2360 | CJ-2360 is a potent and orally active ALK with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potenty activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated. CAS No. 2226742-61-4. Molecular formula: C27H30FN5O2. Mole weight: 475.56. | |
| CJ-42794 | CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist. It inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5. It competitively antagonized cAMP accumulation with a pA2 value of 8.7 in HEK293 cells overexpressing rat prostanoid EP4 receptors. It did not exhibit any remarkable binding to 65 additional proteins, including GPCRs, enzymes, and ion channels. It reversed the inhibitory effects of PGE2 on LPS-induced TNFα production in a concentration-dependent manner. It has excellent pharmacological properties that make it a useful tool for exploring the physiological role of EP4 receptors. Uses: Cj-42794 has excellent pharmacological properties that make it a useful tool for exploring the physiological role of ep4 receptors. Synonyms: CJ-042794; CJ 042794; CJ042794; RQ-00015986, RQ-15986. 4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]benzoic acid; (S)-4-(1-(5-chloro-2-(4-fluorophenoxy)benzaMido)ethyl)benzoic acid; CJ-042794; 4-((S)-1-(2-(4-fluorophenoxy)-5-chlorobenzamido)ethyl)benzoic acid. Grade: >98%. CAS No. 847728-01-2. Molecular formula: C22H17ClFNO4. Mole weight: 413.83. | |
| CJ463 | CJ463 is a potent ans selective Urokinase (uPA) inhibitor, which plays a crucial role in carcinogenesis by facilitating tumor cell invasion and metastasis. It may be a novel agent for treatment of lung cancer. Uses: Cj463 may be a novel agent for treatment of lung cancer. Synonyms: CJ-463; CJ 463; CJ463. (S)-N-(4-carbamimidoylbenzyl)-3-hydroxy-2-((R)-3-hydroxy-2-((phenylmethyl)sulfonamido)propanamido)propanamide. Grade: 98%. CAS No. 600142-19-6. Molecular formula: C21H27N5O6S. Mole weight: 477.54. | |
| CJB 090 dihydrochloride hydrate | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| CJC-1295 | CJC-1295 is a growth hormone releasing hormone (GHRH) analog that can be used for growth hormone (GH) deficiency as a long-acting agent. Synonyms: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2; L-tyrosyl-D-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-glutaminyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-leucyl-L-seryl-L-argininamide. CAS No. 863288-34-0. Molecular formula: C152H252N44O42. Mole weight: 3367.9. | |
| CJC1295 With DAC | CJC1295 is a synthetic analogue of growth hormone-releasing hormone. Uses: Cjc1295 with dac, also known as dac:grf (1-29), is a synthetic modification of the growth hormone releasing hormone (ghrh) peptide. this peptide is designed to stimulate the pituitary gland to produce and release growth hormone (gh) in a more sustained manner than natural ghrh. it contains a series of amino acids designed to mimic the effects of natural ghrh in the body. the addition of dac (drug. Grade: 98%. CAS No. 446262-90-4. Molecular formula: C165H269N47O46. Mole weight: 3647.19. | |
| c-JUN (1-79), GST tagged human | recombinant, expressed in E. coli, ?50% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| C-Jun-amino-terminal kinase-interacting protein 2 (683-692) | C-Jun-amino-terminal kinase-interacting protein 2 (683-692) is a peptide fragment of C-Jun-amino-terminal kinase-interacting protein 2. C-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central role in stress signaling pathways implicated in gene expression, neuronal plasticity, regeneration, cell death, and regulation of cellular senescence. It can be used in Ovarian carcinoma research. | |
| c-Jun Control Cell Extract, Non-Phosphorylated | c-Jun Control Cell Extract, Non-Phosphorylated. Group: Molecular Biology. Pack Sizes: 1x150ul. US Biological Life Sciences. | Worldwide |
| c-Jun Control Cell Extract, Phosphorylated | c-Jun Control Cell Extract, Phosphorylated. Group: Molecular Biology. Pack Sizes: 1x150ul. US Biological Life Sciences. | Worldwide |
| c-Jun Control Cell Extracts | C-Jun is a component of the transcription factor AP-1 that binds and activates transcription at TRE/AP-1 elements. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 (1,2). Extracellular signals including growth factors, transforming oncoproteins and UV irradiation stimulate phosphorylation of c-Jun at Ser63/73 and activate c-Jun dependent transcription. Mutation of Ser63/73 renders c-Jun nonresponsive to mitogenic and stress induced signaling pathways. The MAP kinase homologue, SAPK/JNK, binds to the N-terminal region of c-Jun and phosphorylates c-Jun at Ser63/73. In addition, the activity of SAPK/JNK is stimulated by the same signals that activate c-Jun (3,4). Nonphosphorylated c-Jun (Ser63) II Cell Extracts: Total cell extracts from NIH/3T3 cells, prepared without treatment, serve as a negative control. Group: Biologicals. Grades: Lysate. Pack Sizes: 10Blots. US Biological Life Sciences. | Worldwide |
| c-JUN peptide | c-JUN peptide is a JNK/c-Jun interaction inhibitor. Synonyms: (2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-3-carboxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]-4-oxobutanoic acid. Grade: >98%. CAS No. 610273-01-3. Molecular formula: C121H210N36O34S. Mole weight: 2745.24. | |
| C-jun, proto oncogene human | recombinant, expressed in insect cells, ?80% (SDS-PAGE). Group: Fluorescence/luminescence spectroscopy. | |
| CK0106023 | CK0106023 was specific inhibitor of KSP. In tumor-bearing mice, CK0106023 exhibited antitumor activity comparable to or exceeding that of paclitaxel and caused the formation of monopolar mitotic figures identical to those produced in cultured cells. KSP was most abundant in proliferating human tissues and was absent from cultured postmitotic neurons. Synonyms: CK 0106023; CK-0106023; N-(1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)-4-bromo-N-(3-(dimethylamino)propyl)benzamide. CAS No. 336115-72-1. Molecular formula: C30H32BrClN4O2. Mole weight: 595.97. | |
| CK-119 | CK-119, a dihydropyridazino-pyridazine compound, is a potent IL-1 blocker to inhibit cell growth of fibroblast-like corneal and conjunctival cells mainly through the inhibition of DNA and RNA syntheses but not protein synthesis. Synonyms: diethyl 6-[(4-chlorophenyl)methyl]-1,4-dimethyl-5-oxopyridazino[4,5-c]pyridazine-3,4-dicarboxylate; CK-119; CK119; CK 119; UNII-AL53N923EI; GC-6119; GC 6119; GC6119. Grade: >98%. CAS No. 197917-10-5. Molecular formula: C21H23ClN4O5. Mole weight: 446.88. | |
| CK1 ? 1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1?1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1 ? 2, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1 ? 3, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK 17 | CK 17 is a interleukin-1 antagonist. It can suppress fibroblast proliferation. Synonyms: CK 17; CK17; CK-17; 5-Bromotetrahydro-5-methyl-3-phenyl-2-(phenylimino)-4H-1,3-thiazin-4-one. Grade: 98%. CAS No. 86727-00-6. Molecular formula: C17H15BrN2OS. Mole weight: 375.29. | |
| CK 1827452 | CK-1827452 is a diaryl urea compound that increases cardiac myosin ATPase activity in a dose-dependent manner that is selective for cardiac myosin over non-cardiac myosins. It promotes myosin cross-bridge formation, increasing the duration and amount of myocyte contraction without affecting intracellular calcium or cAMP. It has been shown to increase cardiac efficiency in clinical studies of patients with chronic heart failure. Group: Biochemicals. Alternative Names: Methyl 4- [ [2-Fluoro-3- [N'- (6-methylpyridin-3-yl) ureido] phenyl] methyl] piperazine-1-carboxylate; 4- [ [2-Fluoro-3- [ [ [ (6-methyl-3-pyridinyl) amino] carbonyl] amino] phenyl] methyl] -1-piperazinecarboxylic Acid Methyl Ester; Omecamtiv Mecarbil. Grades: Highly Purified. CAS No. 873697-71-3. Pack Sizes: 5mg, 10mg. Molecular Formula: C??H??FN?O?, Molecular Weight: 401.43. US Biological Life Sciences. | Worldwide |
| CK1 ?, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK1-IN-1 | CK1-IN-1 is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. Synonyms: PUN51207; Compound 1C. CAS No. 1784751-20-7. Molecular formula: C24H15F2N3. Mole weight: 383.39. | |
| CK1-IN-3 | CK1-IN-3 is a casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases. Synonyms: N-(6-Methoxybenzo[d]thiazol-2-yl)-2-(2-methoxyphenyl)acetamide; N-[(2E)-6-methoxy-1,3-benzothiazol-2(3H)-ylidene]-2-(2-methoxyphenyl)acetamide. CAS No. 349438-74-0. Molecular formula: C17H16N2O3S. Mole weight: 328.39. | |
| CK-2130 | CK-2130 is a bio-active imidazolone developed to treat congestive heart failure. It inhibited human platelet aggregation produced by adenosine diphosphate and sodium arachidonate. Uses: Ck-2130 is used to treat congestive heart failure. Synonyms: CK 2130; CK-2130; CK2130. 4-Ethyl-1,3-dihydro-5-[4-[(2-methyl-1H-imidazol)-1-yl]benzoyl]-2H-imidazol-2-one; CK2130; 4-Ethyl-5-[4-(2-methylimidazol-1-yl)benzoyl]-1,3-dihydroimidazol-2-one. Grade: >98 %. CAS No. 101184-07-0. Molecular formula: C16H16N4O2. Mole weight: 296.33. | |
| CK2?1, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK-2289 | CK-2289 is an type III cyclic 3'5'-adenosine monophosphate phosphodiesterase inhibitor. It may be used in the treatment of congestive heart failure. Uses: Ck-2289 may be used in the treatment of congestive heart failure. Synonyms: CK 2289; CK-2289; CK2289. 4-[4-(1H-Imidazol-1-yl)benzoyl]-5-ethyl-1H-imidazol-2(3H)-one; 4-Ethyl-5-[4-(1H-imidazol-1-yl)benzoyl]-1H-imidazol-2(3H)-one; 2H-Imidazol-2-one,4-ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-; 4-Ethyl-1,3-dihydro-5-[4-(1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one. Grade: >98 %. CAS No. 101183-99-7. Molecular formula: C15H14N4O2. Mole weight: 282.30. | |
| CK2 ? 2, active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| CK2/ERK8-IN-1 | CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) and ERK8. It also binds to Pim-1, HIPK2, and DYRK1A. CK2/ERK8-IN-1 induces apoptosis in Jurkat cells when used at concentrations ranging from 10 to 50 μM. Synonyms: TMCB; 4,5,6,7-Tetrabromo-2-(dimethylamino)-1H-benzimidazole-1-acetic acid. Grade: ≥99%. CAS No. 1085822-09-8. Molecular formula: C11H9Br4N3O2. Mole weight: 534.82. | |
| CK2/ERK8-IN-1 | CK2/ERK8-IN-1 is a dual casein kinase 2 (CK2) (Ki of 0.25 μM) and ERK8 (MAPK15, ERK7) inhibitor with IC50s of 0.50 ?M. CK2/ERK8-IN-1 also binds to PIM1, HIPK2 (homeodomain-interacting protein kinase 2), and DYRK1A with Kis of 8.65 μM, 15.25 μM, and 11.9 μM, respectively. CK2/ERK8-IN-1 has pro-apoptotic efficacy[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1085822-09-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-135906. |  |
| CK2 inhibitor 10 | CK2 inhibitor 10 is a potent and ATP-competitive inhibitor of protein kinase (CK2; IC50 values of 32 nM and 46 nM for CK2α and CK2α' respectively). Compound 10 dose-dependently inhibits the kinases. It exhibits potent cytotoxicity towards lung cancer cells A549, colorectal cancer cells HCT-116, and breast cancer cells MCF-7. Synonyms: CK2-IN-3b; 4-(2-(4-methoxybenzamido)thiazol-5-yl)benzoic acid. Grade: 99%. CAS No. 1361229-76-6. Molecular formula: C18H14N2O4S. Mole weight: 354.38. | |
| CK2 inhibitor 2 | CK2 inhibitor 2 is a potent, selective and orally active CK2 inhibitor with favorable antiproliferative and antitumor activities. It has high selectivity for Clk2 (IC50 = 32.69 nM)/CK2 (IC50 = 0.66 nM). Synonyms: 5-(3-chlorophenylamino)-N-(2-hydroxyethyl)benzo[c][2,6]naphthyridine-8-carboxamide; Benzo[c][2,6]naphthyridine-8-carboxamide, 5-[(3-chlorophenyl)amino]-N-(2-hydroxyethyl)-. Grade: ≥98%. CAS No. 2641079-92-5. Molecular formula: C21H17ClN4O2. Mole weight: 392.84. | |
| CK2/PIM1-IN-1 | CK2/PIM1-IN-1 is a CK2 and PIM1 inhibitor, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CAS No. 292640-28-9. Molecular formula: C15H9NO4S2. Mole weight: 331.37. | |
| CK 3197 | CK 3197 is a Phosphoric diester hydrolase inhibitor originated by Bayer HealthCare Pharmaceuticals. CK 3197 has hemodynamic and myocardial energetic effects. In Jan 2007, preclinical for Heart failure in USA was discontinued. Uses: Heart failure. Synonyms: CK 3197; CK-3197; CK3197. 1-benzoyl-5-(4-(4,5-dihydro-2-methyl-1H-imidazol-1-yl)benzoyl)-4-ethyl-1,3-dihydro-2H-Imidazol-2-one. Grade: 98%. CAS No. 132523-92-3. Molecular formula: C23H22N4O3. Mole weight: 402.45. | |
| CK-636 | CK-636 is an Arp2/3 complex inhibitor. CK-636 binds between Arp2 and Arp3, where it appears to block movement of Arp2 and Arp3 into their active conformation. CK-636 inserts into the hydrophobic core of Arp3 and alters its conformation. Synonyms: CK636; CK 636; CK-636; CK0944636; CK-0944636; CK 0944636. CAS No. 442632-72-6. Molecular formula: C16H16N2OS. Mole weight: 284.38. | |
| CK-636 | CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC50 values of 4 ?M, 24 ?M and 32 ?M for human, fission yeast and bovine, respectively. CK636 blocks cell migration. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CK-0944636. CAS No. 442632-72-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-15892. | |
| CK-636 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| CK 666 | CK 666. Group: Biochemicals. Grades: Purified. CAS No. 442633-00-3. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| CK-666 | CK 666 has been found to be an inhibitor of the Arp2/3 complex and could also restrain actin polymerization. Synonyms: 442633-00-3; 2-fluoro-N-[2-(2-methyl-1H-indol-3-yl)ethyl]benzamide; CK-666; CK 666; CK-0944666; 2-Fluoro-N-(2-(2-methyl-1H-indol-3-yl)ethyl)benzamide; 3ukr; UXRKUKRXVWJFER-UHFFFAOYSA-N; Oprea1_850670; SCHEMBL3382638; CHEBI:78843; DTXSID70343330; 2-Fluoro-N-[2-(2-methyl-1H-indol-3-yl)-ethyl]-benzamide; CK666; NSC821559; STK766770; AKOS001725056; CK 666?; NSC-821559; NCGC00370920-01; AS-82972; CK-666, >=98% (HPLC), powder; DA-62359; HY-16926; CS-0012973; F81773; SR-01000536526; SR-01000536526-1; Q27147993; Z1038843750; CKH. Grade: ≥99% by HPLC. CAS No. 442633-00-3. Molecular formula: C18H17FN2O. Mole weight: 296.34. | |
| CK-666 | CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC50=12 ?M). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 442633-00-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-16926. | |
| CK-666 | ?98% (HPLC), powder. Group: Fluorescence/luminescence spectroscopy. | |
| CK 683A | CK 683A is a bio-active chemical,but no detailed information has been published yet. Synonyms: CK 683A; CK683A; CK-683A. 1,7-Bis((1-adamantyl)carbamylguanidino)-4-methyl-4-azaheptane. Grade: 98%. CAS No. 83539-21-3. Molecular formula: C32H57N9O5S. Mole weight: 679.92. | |
| CK7 | CK7, a Cdk2/9 inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367 [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 507487-89-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103646. | |
| CK 869 | CK 869. Group: Biochemicals. Grades: Purified. CAS No. 388592-44-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| CK 869 | CK 869 has been found to inhibit actin polymerization as well as human and bovine actin-related protein 2/3 (Arp2/3) complex. Synonyms: CK-869; CK 869; CK869; CK-0157869; CK 0157869; CK0157869; 2-(3-Bromophenyl)-3-(2,4-dimethoxyphenyl)-4-thiazolidinone. Grade: ≥98% by HPLC. CAS No. 388592-44-7. Molecular formula: C17H16BrNO3S. Mole weight: 394.28. | |
| CK-869 | CK-869 is an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor, with an IC50 of 7 ?M. Uses: Scientific research. Group: Signaling pathways. CAS No. 388592-44-7. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16927. | |
| CK-869 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| CKD-516 | This active molecular is a tubulin polymerisation inhibitor which is applicated for solid cancer treatment. CKD-516 disruptes tubulin of the endothelial cytoskeleton selectively. In Jun 2012, a South Korea company, Chong Kun Dang initiated enrolment in a phase I trial for solid tumours treatment in South Korea. In Dec 2014, Phase-I clinical trials in Solid tumours in South Korea was on going. Uses: Solid tumours. Synonyms: CKD-516 HCl; CKD 516 HCl; CKD516 HCl; (2S)-2-amino-3-methyl-N-[4-[3-(1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl]-1,3-thiazol-2-yl]butanamide; hydrochloride; 1188371-47-2 (free base). Grade: 98%. CAS No. 1188371-47-2. Molecular formula: C26H28N6O5S. Mole weight: 536.6. | |
| CKD-516 HCl | CKD-516 is tubulin inhibitor for solid cancer, which was initiated phase 1 trial in Korea in 2010. CKD-516 selectively disrupted tubulin component of the endothelial cytoskeleton. Serial DCE-MRI showed a significant decrease in K-trans and IAUGC parameters from baseline at 4 h (39.9 % in K-trans; -45.0 % in IAUGC) and at 24 h (-32.2 % in K-trans; -36.5 % in IAUGC), and a significant recovery at 48 h (22.9 % in K-trans; 34.8 % in IAUGC) following administration of CKD-516 at a 0.7-mg/kg dose. When the tumors were stratified according to the initial K-trans value of 0.1, tumors with a high K-trans?>?0.1 which was indicative of having well-developed pre-existing vessels, showed greater reduction in K-trans and IAUGC values. On histologic examination, the degree of necrosis of treated tumors was significantly greater than that of untreated tumors. In summary, CKD-516 is an effective VDA which results in rapid vascular shutdown by targeting the tubulin component of tumor vessels and thus leads to necrosis. Synonyms: Valecobulin hydrochloride; CKD516 hydrochloride; CKD 516 hydrochloride. CAS No. 1240321-53-2. Molecular formula: C26H29ClN6O5S. Mole weight: 573.07. | |
| CKD-602 | CKD-602 Inhibitor. Uses: Scientific use. Product Category: T7551. CAS No. 213819-48-8. |  |
| CKD-711 | It is produced by the strain of Streptomyces sp. CK-4416. CKD-711 strongly inhibited mammalian α-glucosidase activity, but weakly inhibited mammalian α-amylase from microorganism and mammal, which was similar to acarbose in vivo and in vitro. Synonyms: 4-Deoxy-4-{[(1R,2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)-7-oxabicyclo[4.1.0]hept-2-yl]amino}-α-D-glucopyranosyl-(1->4)-α-D-glucopyranosyl-(1->4)-D-glucopyranose. Molecular formula: C25H43NO20. Mole weight: 677.60. | |
| CKI 7 dihydrochloride | CKI 7 is a CK1 inhibitor, and also inhibits SGK, S6K1 and MSK1. In combination with SB 431542, CKI 7 was shown to induce retinal cell differentiation from human ESCs and iPSCs. Synonyms: CKI-7 dihydrochloride; N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulphonamide dihydrochloride. Grade: >98%. CAS No. 1177141-67-1. Molecular formula: C11H14Cl3N3O2S. Mole weight: 358.67. | |
| CKI-7 dihydrochloride | ?98% (HPLC), solid. Group: Fluorescence/luminescence spectroscopy. | |
| CKI-7 free base | CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC 50 of 6 μM and a K i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK , ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases [1] [2] [3] [4]. Uses: Scientific research. Group: Signaling pathways. CAS No. 120615-25-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-133028. | |
Our database is helping our users find suppliers everyday.
